<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2024q2"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2024q2/ffd-2024q2.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2025-02-20</startDate>
            <endDate>2025-02-20</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-20</startDate>
            <endDate>2025-02-20</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-206">S-3</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-207">424B5</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-208">EX-FILING FEES</ffd:FeeExhibitTp>
    <ffd:RegnFileNb contextRef="rc" id="ixv-209">333-285059</ffd:RegnFileNb>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-210">0001178879</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-211">AMICUS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <ffd:FnlPrspctsFlg contextRef="rc" id="ixv-212">false</ffd:FnlPrspctsFlg>
    <ffd:FormTp contextRef="rc" id="ixv-237">S-3</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-238">AMICUS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-239">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-240">Common stock, $0.01 par value per share</ffd:OfferingSctyTitl>
    <ffd:Rule415a6Flg contextRef="offrl_1" id="ixv-241">true</ffd:Rule415a6Flg>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-242"
      unitRef="USD">164206529.00</ffd:MaxAggtOfferingPric>
    <ffd:CfwdFormTp contextRef="offrl_1" id="ixv-243">S-3</ffd:CfwdFormTp>
    <ffd:CfwdPrrFileNb contextRef="offrl_1" id="ixv-244">333-262987</ffd:CfwdPrrFileNb>
    <ffd:CfwdPrrFctvDt contextRef="offrl_1" id="ixv-245">2022-02-22</ffd:CfwdPrrFctvDt>
    <ffd:CfwdPrevslyPdFee
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-246"
      unitRef="USD">18096.00</ffd:CfwdPrevslyPdFee>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="INF" id="ixv-247" unitRef="USD">164206529.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="INF" id="ixv-248" unitRef="USD">0.00</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="rc" decimals="INF" id="ixv-249" unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="INF" id="ixv-250" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="INF" id="ixv-251" unitRef="USD">0.00</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_1" id="ixv-252">In accordance with Rule 415(a)(6) of the Securities Act of 1933, as amended (the "Securities Act"), the registrant is hereby including in this registration statement (the "Registration Statement") securities that were previously registered on the registration statement on Form S-3ASR, File No. 333-262987, filed with the SEC on February 24, 2022, pursuant to a prospectus supplement filed by the registrant on November 7, 2022, but that have not yet been sold by the registrant. Pursuant to Rule 415(a)(6), the fee previously paid by the registrant with respect to such unsold common shares continues to apply to such shares and no fees are due with respect to such shares. Pursuant to Rule 416(a) under the Securities Act, this Registration Statement shall be deemed to cover any additional number of common shares as may be issued from time to time as a result of stock splits, stock dividends or similar transactions.</ffd:OfferingNote>
</xbrl>
